Narcisa Mesaros

1.7k total citations
41 papers, 970 citations indexed

About

Narcisa Mesaros is a scholar working on Epidemiology, Microbiology and Infectious Diseases. According to data from OpenAlex, Narcisa Mesaros has authored 41 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 28 papers in Microbiology and 10 papers in Infectious Diseases. Recurrent topics in Narcisa Mesaros's work include Bacterial Infections and Vaccines (28 papers), Pneumonia and Respiratory Infections (26 papers) and Influenza Virus Research Studies (11 papers). Narcisa Mesaros is often cited by papers focused on Bacterial Infections and Vaccines (28 papers), Pneumonia and Respiratory Infections (26 papers) and Influenza Virus Research Studies (11 papers). Narcisa Mesaros collaborates with scholars based in Belgium, United States and India. Narcisa Mesaros's co-authors include Françoise Van Bambeke, Paul M. Tulkens, Y. Glupczynski, M. Roussel‐Delvallez, Johan Van Eldere, F. Jacobs, Patrick Plésiat, Patrick Lebecque, Patrice Nordmann and Anne Malfroot and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Antimicrobial Chemotherapy and Vaccine.

In The Last Decade

Narcisa Mesaros

36 papers receiving 931 citations

Peers

Countries citing papers authored by Narcisa Mesaros

Since Specialization

Citations

This map shows the geographic impact of Narcisa Mesaros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narcisa Mesaros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narcisa Mesaros more than expected).

Fields of papers citing papers by Narcisa Mesaros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narcisa Mesaros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narcisa Mesaros. The network helps show where Narcisa Mesaros may publish in the future.

Co-authorship network of co-authors of Narcisa Mesaros

This figure shows the co-authorship network connecting the top 25 collaborators of Narcisa Mesaros. A scholar is included among the top collaborators of Narcisa Mesaros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Narcisa Mesaros. Narcisa Mesaros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enhancing vaccine clinical trials participation among elderly: challenges and strategies 2025 ·Trials ·Paul Gillard, Samer Nakhle, (unknown), Ouzama Henry, Narcisa Mesaros	1
2	Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial 2023 ·Respiratory Investigation ·Shady Kotb, Miwa Haranaka, Nicolas Folschweiller, (unknown), (unknown), Nathalie De Schrevel, Marie‐Pierre David, Narcisa Mesaros, Veronica Hulstrøm	11
3	Safety of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine when administered during pregnancy as part of the maternal immunization program in Brazil: a single center, observational, retrospective, cohort study 2019 ·Human Vaccines & Immunotherapeutics ·(unknown), Narcisa Mesaros, (unknown), Maria Angeles Ceregido, (unknown), (unknown)	9
4	Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants 2018 ·Human Vaccines & Immunotherapeutics ·Nicola P. Klein, Remon Abu‐Elyazeed, Yaela Baine, Brigitte Cheuvart, (unknown), Narcisa Mesaros	3
5	Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults 2018 ·Vaccine ·Donald M. Brandon, Murray Kimmel, Sherine Kuriyakose, Lusiné Kostanyan, Narcisa Mesaros	10
6	A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK 2018 ·Vaccine ·Robin Marlow, Sherine Kuriyakose, Narcisa Mesaros, Htay Htay Han, Richard Tomlinson, Saul N. Faust, Matthew D. Snape, Andrew J. Pollard, Adam Finn	12
7	Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study 2018 ·Human Vaccines & Immunotherapeutics ·Ki Hwan Kim, Chun Soo Kim, Hwang Min Kim, (unknown), (unknown), (unknown), Dong Ho Kim, Pyoung‐Han Hwang, Ji Whan Han, (unknown), Joon Hyung Kim, Naveen Karkada, Narcisa Mesaros, (unknown), Jong‐Hyun Kim	3
8	Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants 2017 ·Vaccine ·Nicola P. Klein, Remon Abu‐Elyazeed, (unknown), (unknown), Leonard B. Weiner, (unknown), (unknown), Meera Varman, Robert W. Frenck, Brigitte Cheuvart, Yaela Baine, Jacqueline M. Miller, Maarten Leyssen, Narcisa Mesaros, Sumita Roy–Ghanta	0
9	Five-year Antibody Persistence and Safety Following a Booster Dose of Combined Haemophilus influenzae Type b–Neisseria meningitidis Serogroup C–Tetanus Toxoid Conjugate Vaccine 2012 ·The Pediatric Infectious Disease Journal ·Juan Carlos Tejedor Torres, José Merino, Manuel Moro, (unknown), (unknown), Félix Omeñaca, José García-Sicilia, David Moreno‐Pérez, Jesús Ruíz-Contreras, Fernándo Centeno Malfaz, Francisco Barrio, (unknown), (unknown), (unknown), (unknown), (unknown), Dominique Boutriau, Jacqueline M. Miller, Narcisa Mesaros	5
10	The safety profile ofHaemophilus influenzaetype b–Neisseria meningitidisserogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY) 2012 ·Human Vaccines & Immunotherapeutics ·(unknown), Kristina A. Bryant, Terry Nolan, Noris Pavía-Ruz, (unknown), (unknown), Christopher J. Cohen, Emmanuel Aris, Narcisa Mesaros, Jacqueline M. Miller	9
11	Three-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type b (Hib)–Neisseria meningitidis Serogroup C-tetanus Toxoid Conjugate Vaccine in Hib-primed Toddlers 2012 ·The Pediatric Infectious Disease Journal ·Robert Booy, Peter Richmond, Terry Nolan, Jodie McVernon, Helen Marshall, Michael D. Nissen, Graham Reynolds, John B. Ziegler, Tanya Stoney, Leon Heron, Stephen B. Lambert, Narcisa Mesaros, (unknown), Jacqueline M. Miller	8
12	A Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C Tetanus Toxoid Conjugate Vaccine Is Immunogenic and Well-tolerated When Coadministered With Diphtheria, Tetanus, Acellular Pertussis Hepatitis B–inactivated Poliovirus at 3, 5 and 11 Months of Age 2012 ·The Pediatric Infectious Disease Journal ·Timo Vesikari, Aino Forstén, (unknown), (unknown), (unknown), Narcisa Mesaros, Dominique Boutriau	6
13	Combined Haemophilus Influenzae Type B-Neisseria Meningitidis Serogroup C Vaccine Is Immunogenic and Well Tolerated in Preterm Infants When Coadministered With Other Routinely Recommended Vaccines 2011 ·The Pediatric Infectious Disease Journal ·Félix Omeñaca, Javier Arı́stegui, Juan Carlos Tejedor Torres, David Moreno‐Pérez, Jesús Ruíz-Contreras, José Merino, (unknown), Tomás Sánchez‐Tamayo, (unknown), (unknown), (unknown), Narcisa Mesaros, Jacqueline M. Miller	6
14	Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine 2010 ·The Pediatric Infectious Disease Journal ·Terry Nolan, Peter Richmond, Helen Marshall, Jodie McVernon, Karyn Alexander, Narcisa Mesaros, Emmanuel Aris, Jacqueline M. Miller, Jan Poolman, Dominique Boutriau	21
15	Persistence of Immunity Following a Booster Dose of Haemophilus Influenzae Type B-Meningococcal Serogroup C Glycoconjugate Vaccine 2010 ·The Pediatric Infectious Disease Journal ·Ameneh Khatami, Matthew D. Snape, Tessa M. John, (unknown), (unknown), (unknown), Dominique Boutriau, Narcisa Mesaros, Jacek Wysocki, Andrzej Gałaj, Ly‐Mee Yu, Andrew J. Pollard	27
16	In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy 2010 ·International Journal of Antimicrobial Agents ·Mickaël Riou, Sylviane Carbonnelle, Laëtitia Avrain, Narcisa Mesaros, Jean‐Paul Pirnay, Florence Bilocq, Daniël De Vos, Anne Simon, Denis Piérard, Frédérique Jacobs, Anne Dediste, Paul M. Tulkens, Françoise Van Bambeke, Y. Glupczynski	65
17	IMMEDIATE AND LONGER TERM IMMUNOGENICITY OF A SINGLE DOSE OF THE COMBINED HAEMOPHILUS INFLUENZAE TYPE B-NEISSERIA MENINGITIDIS SEROGROUP C-TETANUS TOXOID CONJUGATE VACCINE IN PRIMED TODDLERS 12 TO 18 MONTHS OF AGE 2010 ·The Pediatric Infectious Disease Journal ·Robert Booy, Peter Richmond, Terry Nolan, Jodie McVernon, Helen Marshall, Michael D. Nissen, Graham Reynolds, John B. Ziegler, Leon Heron, Stephen B. Lambert, (unknown), Narcisa Mesaros, Dominique Boutriau	11
18	Immunogenicity and Safety of a Combined Haemophilus influenzae type b - Neisseria meningitidis serogroups C and Y - tetanus toxoid conjugate (HibCY) candidate vaccine 2007 ·Narcisa Mesaros	1
19	Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations 2007 ·Journal of Antimicrobial Chemotherapy ·Laëtitia Avrain, M.I. Garvey, Narcisa Mesaros, Y. Glupczynski, M. P. Mingeot-Leclercq, Laura J. V. Piddock, Paul M. Tulkens, R. Vanhoof, Françoise Van Bambeke	27
20	L'efflux des antibiotiques: un mécanisme ubiquitaire conduisant à la résistance. État de la question et implications microbiologiques et cliniques 2005 ·Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) ·Narcisa Mesaros, Françoise Van Bambeke, Y. Glupczynski, R. Vanhoof, Paul M. Tulkens	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact